18889881171
Kalkine 0
countryflagUS

Arvinas Inc

Healthcare US ARVN

8.02USD
0.23(2.95%)

Last update at 2025-07-14T16:49:00Z

Day Range

7.748.11
LowHigh

52 Week Range

5.9037.38
LowHigh

Fundamentals

  • Previous Close 7.79
  • Market Cap473.71M
  • Volume473781
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-91.40000M
  • Revenue TTM426.90M
  • Revenue Per Share TTM5.92
  • Gross Profit TTM 426.90M
  • Diluted EPS TTM-0.66

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -251.00000M -191.00000M -119.33206M -70.29223M -41.48047M
Minority interest - - - - -
Net income -271.90000M -183.20000M -111.78671M -62.13204M -41.48047M
Selling general administrative 79.60M 61.60M 38.30M 27.31M 12.93M
Selling and marketing expenses - - - - -
Gross profit 131.40M 46.70M 21.80M 42.98M 14.32M
Reconciled depreciation 8.20M 6.00M 4.02M 2.25M 0.71M
Ebit -271.40000M -201.30000M -128.88198M -53.77742M -44.50808M
Ebitda -263.20000M -195.30000M -124.85748M -51.52451M -43.80208M
Depreciation and amortization 8.20M 6.00M 4.02M 2.25M 0.71M
Non operating income net other 1.60M 4.40M 5.59M -18.68214M 2.38M
Operating income -263.20000M -195.30000M -124.85748M -51.52451M -43.80208M
Other operating expenses 394.60M 242.00M 146.66M 94.50M 58.13M
Interest expense 12.00M 0.10M 0.07M 0.09M 0.06M
Tax provision 20.90M - - - -
Interest income 12.20M 1.90M 3.59M 4.56M 2.47M
Net interest income 12.20M 1.80M 3.52M 4.47M 2.41M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 20.90M -7.80000M -7.54536M -8.16019M 2.38M
Total revenue 131.40M 46.70M 21.80M 42.98M 14.32M
Total operating expenses 394.60M 242.00M 146.66M 94.50M 58.13M
Cost of revenue - - - - 0.00000M
Total other income expense net 12.20M 4.30M 5.53M -18.76771M -0.09105M
Discontinued operations - - - - -
Net income from continuing ops -282.50000M -191.00000M -119.33206M -70.29223M -41.48047M
Net income applicable to common shares -282.50000M -191.00000M -119.33206M -70.29223M -239.84722M
Preferred stock and other adjustments - - - - 198.37M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1091.40M 1304.60M 1268.80M 1581.60M 717.37M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 14.20M 6.50M 21.40M 19.70M 6.11M
Total liab 529.70M 644.60M 703.90M 799.90M 75.11M
Total stockholder equity 561.70M 660.00M 564.90M 781.70M 642.26M
Deferred long term liab - - - - -
Other current liab 57.20M 74.40M 69.00M 23.10M 18.86M
Common stock 0.10M 0.10M 0.10M - 0.05M
Capital stock 0.10M 0.10M 0.10M 0.00000M 0.05M
Retained earnings -1531.60000M -1332.70000M -965.40000M -682.90000M -491.88891M
Other liab - - 405.10M 534.30M 22.94M
Good will - - - - -
Other assets - 0.00000M 10.80M 0.10M 0.03M
Cash 100.50M 317.20M 81.30M 108.30M 588.37M
Cash and equivalents - - - - -
Total current liabilities 229.80M 257.10M 295.10M 261.70M 49.09M
Current deferred revenue 156.20M 163.00M 218.60M 206.20M 22.15M
Net debt -90.80000M -313.80000M -75.80000M -103.30000M -584.33297M
Short term debt 1.80M 2.10M 1.80M 1.10M 0.95M
Short long term debt - - - - -
Short long term debt total 9.70M 3.40M 5.50M 5.00M 4.04M
Other stockholder equity 2092.20M 1995.70M 1549.40M 1469.20M 1133.54M
Property plant equipment - - 13.40M 16.60M 12.26M
Total current assets 1067.30M 1280.20M 1240.20M 1552.50M 703.09M
Long term investments - - - - -
Net tangible assets - - 564.90M 781.70M 642.26M
Short term investments 938.90M 949.30M 1124.00M 1394.30M 100.16M
Net receivables 13.70M 7.20M 8.00M 25.70M 8.44M
Long term debt 0.60M 0.80M 1.00M 1.00M 2.00M
Inventory - - 5.50M 4.50M -
Accounts payable 13.20M 17.60M 5.70M 31.30M 7.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.00M -3.10000M -19.20000M -4.60000M 0.56M
Additional paid in capital - - - - -
Common stock total equity - - 0.10M - 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - -965.40000M -682.90000M -491.88891M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.10M 10.40M 10.80M 12.50M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 24.10M 24.40M 28.60M 29.10M 14.28M
Capital lease obligations 9.10M 2.40M 4.50M 4.00M 2.04M
Long term debt total - - 1.00M 1.00M 2.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 249.60M -1308.90000M 170.70M -86.85254M -176.83470M
Change to liabilities 20.20M 719.20M 12.85M 5.21M 2.46M
Total cashflows from investing activities 242.80M -1313.60000M 164.25M -93.09656M -179.66536M
Net borrowings - - - -0.16961M 1.83M
Total cash from financing activities 4.70M 278.60M 504.67M 139.74M 168.06M
Change to operating activities - -26.90000M 6.34M -2.07020M -3.11156M
Net income -282.50000M -191.00000M -119.33206M -70.29223M -41.48047M
Change in cash -26.00000M -475.60000M 579.16M 6.02M -27.72234M
Begin period cash flow 112.80M 588.40M 9.21M 3.19M 30.91M
End period cash flow 86.80M 112.80M 588.37M 9.21M 3.19M
Total cash from operating activities -273.50000M 559.40M -89.75693M -40.62634M -16.11767M
Issuance of capital stock 0.00000M 264.60M 525.64M 137.69M 169.58M
Depreciation 8.20M 6.00M 4.02M 2.25M 0.71M
Other cashflows from investing activities - - - -86.85254M -176.83470M
Dividends paid - - - -3.42177M 60.50M
Change to inventory - -26.90000M 6.34M -2.07020M -3.26156M
Change to account receivables 14.00M -14.00000M -1.00000M 2.78M 22.22M
Sale purchase of stock 4.70M 14.00M -29.23483M -0.59713M -3.42359M
Other cashflows from financing activities 242.80M 14.00M 8.26M 6.25M 117.57M
Change to netincome 75.50M 65.70M 29.84M 20.07M 11.82M
Capital expenditures 6.80M 4.70M 6.45M 6.24M 2.83M
Change receivables 17.70M -17.30000M -2.16283M -1.24903M 21.01M
Cash flows other operating -116.40000M 668.30M -15.76795M 3.90M -10.89947M
Exchange rate changes - - - - -
Cash and cash equivalents changes -26.00000M -475.60000M 579.16M 6.02M -27.72234M
Change in working capital -82.60000M 678.30M -5.93968M 7.17M 12.57M
Stock based compensation 75.50M 57.10M 30.23M 20.07M 11.63M
Other non cash items 7.90M 9.80M 1.65M 0.17M 0.27M
Free cash flow -280.30000M 554.70M -96.20447M -46.87037M -18.94833M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARVN
Arvinas Inc		 0.23 2.95% 8.02 - 17.70 1.11 0.72 5.69 -1.6185
NVO
Novo Nordisk A/S		 0.27 0.39% 69.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.49 0.70% 70.49 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.04 0.86% 472.89 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.77 0.84% 572.51 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Inc

5 Science Park, New Haven, CT, United States, 06511

Key Executives

Name Title Year Born
Dr. John G. Houston Ph.D. CEO, Pres & Director 1960
Mr. Sean A. Cassidy CPA, CPA, M.B.A. CFO & Treasurer 1970
Dr. Ian Taylor Ph.D. Chief Scientific Officer 1962
Dr. Ronald A. Peck Chief Medical Officer NA
Mr. Jeff Boyle VP of Investor Relations NA
Mr. Matthew Batters J.D. Gen. Counsel & Corp. Sec. 1975
Dr. Randy Teel Ph.D. Sr. VP of Corp. & Bus. Devel. 1979
Mr. Steve Weiss Sr. VP & Chief HR Officer 1970
Dr. John A. Grosso Ph.D. Sr. VP of R&D Technical Operations 1957
Ms. Angela M. Cacace Ph.D. Sr. VP of Neuroscience & Platform Biology 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.